Suven Life Sciences granted patents for neurodegenerative drug

Tags: Companies
Pharmaceutical firm Suven Life Sciences has been granted three product patents -- one each by South Korea, China and Canada -- for drug used in the treatment of neurodegenerative diseases.

Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.

In a BSE filing the company said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

These patents are valid through 2029, 2029 and 2031, respectively, the company said in a BSE filing.

Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 14 granted patents from South Korea, 14 from China and 16 from Canada, respectively.

EDITORIAL OF THE DAY

  • Time for a reality check on AIDS

    Is the fear of Human Immuno-deficiency Virus (HIV) infection leading to Acquired Immuno-deficiency Syndrome (AIDS) in India?

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

<b>Disequilibrium:</b> The Looking glass war

In the looking glass war, where bitter adversaries - Ratan ...

Ananda Majumdar

<b>Ruminations:</b> How JP can wake up Cong

The Congress party has clearly missed a trick with its ...

Sachin Shridhar

The quagmire called kashmir

For the past three decades, the separatist leaders have claimed ...